On March 18, 2026, Lixte Biotechnology Holdings, Inc. announced an amendment to the employment agreement of its Chief Executive Officer, Geordan Pursglove. The amendment, approved by the company's Compensation Committee and Board of Directors, raises Pursglove's annual base salary from $240,000 to $360,000, effective January 1, 2026. This increase reflects the company's commitment to retaining top leadership talent and aligns with its strategic goals for growth and operational execution. The amendment is part of a broader strategy to enhance governance controls and ensure the company remains competitive in the biotechnology sector. The details of the amendment are documented in the company's Form 8-K filing with the SEC, which includes the full text of the amended employment agreement as Exhibit 10.1. This move is expected to have a small positive effect on the company's stock price as it signals confidence in the leadership and future direction of the company.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.